Details
Stereochemistry | ACHIRAL |
Molecular Formula | C28H37N3O3 |
Molecular Weight | 463.6117 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOCCN1C(=NC2=CC=CC=C12)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3
InChI
InChIKey=ACCMWZWAEFYUGZ-UHFFFAOYSA-N
InChI=1S/C28H37N3O3/c1-4-34-20-19-31-25-8-6-5-7-24(25)29-26(31)22-14-17-30(18-15-22)16-13-21-9-11-23(12-10-21)28(2,3)27(32)33/h5-12,22H,4,13-20H2,1-3H3,(H,32,33)
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/25878559 | https://medical.azureedge.net/pdf/28433.pdf?v=636220857643656872 | https://www.faesfarma.com/wp-content/uploads/2015/07/AI-20110329-EN.pdf
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/25878559 | https://medical.azureedge.net/pdf/28433.pdf?v=636220857643656872 | https://www.faesfarma.com/wp-content/uploads/2015/07/AI-20110329-EN.pdf
Bilastine is a new second generation H1-antihistamine recently approved for the symptomatic treatment of allergic rhinitis (AR) and chronic urticaria (CU). Bilastine is an H1 receptor inverse agonist. Bilastine also exerts anti-inflammatory activity by inhibiting the release of histamine, IL-4 and tumor necrosis factor (TNF)-α from human mast cells and granulocytes. Common side effects are headache and drowsiness.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 |
64.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Bilaxten Approved UseBilastine is used to relieve the symptoms of hayfever (sneezing, itchy, runny, blocked-up nose and
red and watery eyes) and other forms of allergic rhinitis. It may also be used to treat itchy
skin rashes (hives or urticaria). Launch Date2010 |
|||
Palliative | Bilaxten Approved UseBilastine is used to relieve the symptoms of hayfever (sneezing, itchy, runny, blocked-up nose and
red and watery eyes) and other forms of allergic rhinitis. It may also be used to treat itchy
skin rashes (hives or urticaria). Launch Date2010 |
|||
Palliative | Bilaxten Approved UseBilastine is used to relieve the symptoms of hayfever (sneezing, itchy, runny, blocked-up nose and
red and watery eyes) and other forms of allergic rhinitis. It may also be used to treat itchy
skin rashes (hives or urticaria). Launch Date2010 |
PubMed
Title | Date | PubMed |
---|---|---|
Comparative efficacy of bilastine, levocetirizine and desloratadine updosing in chronic urticaria. | 2016 |
|
Bilastine in allergic rhinoconjunctivitis and urticaria: a practical approach to treatment decisions based on queries received by the medical information department. | 2017 |
|
Corrigendum to "Application of Analytical Quality by Design concept for bilastine and its degradation impurities determination by hydrophilic interaction liquid chromatographic method" [J. Pharm. Biomed. Anal. 125 (2016) 385-393]. | 2017 May 10 |
Patents
Sample Use Guides
Bilastine gave mild positive results for two uptake transporters, OATP2B1 and OCT1, mainly located in liver and intestine. Bilastine IC50 was determined for these two transporters and (based in previous knowledge), also for P-gp. The assay was carried out at seven bilastine concentrations ranging from 0.41 to 300 M. Bilastine showed poor inhibition, as values of IC50 obtained for all the three transporters were ≥ 300 M.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Dec 15 15:35:15 GMT 2023 , Edited by admin on Fri Dec 15 15:35:15 GMT 2023
|
||
|
WHO-VATC |
QR06AX29
Created by
admin on Fri Dec 15 15:35:15 GMT 2023 , Edited by admin on Fri Dec 15 15:35:15 GMT 2023
|
||
|
WHO-ATC |
R06AX29
Created by
admin on Fri Dec 15 15:35:15 GMT 2023 , Edited by admin on Fri Dec 15 15:35:15 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB11591
Created by
admin on Fri Dec 15 15:35:15 GMT 2023 , Edited by admin on Fri Dec 15 15:35:15 GMT 2023
|
PRIMARY | |||
|
C73045
Created by
admin on Fri Dec 15 15:35:15 GMT 2023 , Edited by admin on Fri Dec 15 15:35:15 GMT 2023
|
PRIMARY | |||
|
185460
Created by
admin on Fri Dec 15 15:35:15 GMT 2023 , Edited by admin on Fri Dec 15 15:35:15 GMT 2023
|
PRIMARY | |||
|
C445659
Created by
admin on Fri Dec 15 15:35:15 GMT 2023 , Edited by admin on Fri Dec 15 15:35:15 GMT 2023
|
PRIMARY | |||
|
202189-78-4
Created by
admin on Fri Dec 15 15:35:15 GMT 2023 , Edited by admin on Fri Dec 15 15:35:15 GMT 2023
|
PRIMARY | |||
|
4353
Created by
admin on Fri Dec 15 15:35:15 GMT 2023 , Edited by admin on Fri Dec 15 15:35:15 GMT 2023
|
PRIMARY | |||
|
DTXSID5057678
Created by
admin on Fri Dec 15 15:35:15 GMT 2023 , Edited by admin on Fri Dec 15 15:35:15 GMT 2023
|
PRIMARY | |||
|
CHEMBL1742423
Created by
admin on Fri Dec 15 15:35:15 GMT 2023 , Edited by admin on Fri Dec 15 15:35:15 GMT 2023
|
PRIMARY | |||
|
7905
Created by
admin on Fri Dec 15 15:35:15 GMT 2023 , Edited by admin on Fri Dec 15 15:35:15 GMT 2023
|
PRIMARY | |||
|
100000129239
Created by
admin on Fri Dec 15 15:35:15 GMT 2023 , Edited by admin on Fri Dec 15 15:35:15 GMT 2023
|
PRIMARY | |||
|
SUB37845
Created by
admin on Fri Dec 15 15:35:15 GMT 2023 , Edited by admin on Fri Dec 15 15:35:15 GMT 2023
|
PRIMARY | |||
|
PA1123N395
Created by
admin on Fri Dec 15 15:35:15 GMT 2023 , Edited by admin on Fri Dec 15 15:35:15 GMT 2023
|
PRIMARY | |||
|
m2490
Created by
admin on Fri Dec 15 15:35:15 GMT 2023 , Edited by admin on Fri Dec 15 15:35:15 GMT 2023
|
PRIMARY | Merck Index | ||
|
BILASTINE
Created by
admin on Fri Dec 15 15:35:15 GMT 2023 , Edited by admin on Fri Dec 15 15:35:15 GMT 2023
|
PRIMARY |
ACTIVE MOIETY